US Market News
2月前
Thermo Fisher Scientific Reports First Quarter 2026 ResultsApril 23, 2026 6:00 AM
Business Wire
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.
First Quarter Highlights
First quarter revenue grew 6% to $11.01 billion.
First quarter GAAP diluted earnings per share (EPS) grew 11% to $4.43.
First quarter adjusted EPS grew 6% to $5.44.
Delivered excellent performance in the first quarter, demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company.
Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This included the Thermo Scientific™ Glacios™ 3 Cryo-TEM, a next-generation cryo-transmission electron microscope designed to enable installation in a broader range of lab spaces, democratizing access to cryo-EM for use in structural biology; the Thermo Scientific™ TSQ Certis™ triple quadrupole mass spectrometer, which enhances productivity and reliability by delivering faster, high-quality results to support analytical testing across pharmaceutical and applied laboratories; the Thermo Scientific™ Niton™ XL5e Handheld XRF Analyzer, which enables industrial and applied customers to improve the speed and accuracy of identifying materials in the field; and the Gibco™ CTS™ Compleo™ Fill and Finish System, which increases productivity and reliability in cell therapy manufacturing, supporting scalable production of advanced therapies.
Strengthened our industry-leading commercial engine and deepened our trusted partner status with customers. During the quarter, we announced a strategic collaboration with NVIDIA, combining our leadership in laboratory technologies with NVIDIA’s AI capabilities to advance scientific instrumentation, improve laboratory performance and accelerate scientific breakthroughs. We also announced a strategic collaboration with SHL Medical to deliver fully integrated sterile fill-finish and device assembly solutions, advancing our U.S. drug product manufacturing capabilities and helping pharma and biotech customers accelerate development and commercialization of important medicines.
Continued to successfully execute our capital deployment strategy. During the quarter, we completed the acquisition of Clario, an industry-leading provider of endpoint data solutions, repurchased $3.0 billion of stock and increased our dividend by 10%.
“We delivered a strong start to the year, reflecting excellent execution by our team, as we leveraged the PPI Business System to drive operational excellence and enable our customers’ success,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. “We continued to make great progress executing our strategy, further strengthening our capabilities with the addition of Clario.”
Casper added, “Looking ahead, we are well positioned to deliver a strong year. As the trusted partner to our customers, we are uniquely equipped to help them accelerate their innovation and enhance their productivity. Through our global scale and the power of the PPI Business System, we will continue to actively manage the company to create value for our stakeholders and build an even brighter future for our company.”
First Quarter 2026
Revenue for the first quarter of 2026 grew 6% to $11.01 billion, versus $10.36 billion in the same quarter of 2025. Organic revenue growth was 1%.
GAAP Earnings Results
GAAP diluted EPS in the first quarter of 2026 was $4.43, 11% growth versus the first quarter of 2025. GAAP operating income for the first quarter of 2026 was $1.86 billion, 9% higher than the year-ago quarter. GAAP operating margin was 16.9%, compared with 16.6% in the first quarter of 2025.
Non-GAAP Earnings Results
Adjusted EPS for the first quarter of 2026 was $5.44, 6% growth versus the first quarter of 2025. Adjusted operating income for the first quarter of 2026 was $2.40 billion, 6% higher than the year-ago quarter. Adjusted operating margin was 21.8%, compared with 21.9% in the first quarter of 2025.
Annual Guidance for 2026
The company will provide updated 2026 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Time.
Use of Non-GAAP Financial Measures
Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, and organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.” The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.
Note on Presentation
Certain amounts and percentages reported within this press release are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.
Conference Call
Thermo Fisher Scientific will hold its earnings conference call today, April 23, 2026, at 8:30 a.m. Eastern Time. During the call, the company will discuss its financial performance, as well as future expectations.
The call will be webcast live on the “Investors” section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 470-1428 within the U.S. or +1 (646) 844-6383 outside the U.S. The access code is 723173.
The earnings press release and related information can also be found on the Investor Relations section of our website, under the heading “Financials”. A replay of the call will be available under “News, Events & Presentations” through Wednesday, July 22, 2026.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Safe Harbor Statement
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent reports on Form 10-K and Form 10-Q under the heading “Risk Factors.” These filings are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” These forward-looking statements are based on our current expectations and speak only as of the date of this press release. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, in the event of new information, future developments or otherwise.
Condensed Consolidated Statements of Income (unaudited)
Three months ended
March 28,
% of
March 29,
% of
(Dollars in millions except per share amounts)
2026
Revenues
2025
Revenues
Revenues
$
11,005
$
10,364
Costs and operating expenses:
Cost of revenues (a)
6,529
59.3
%
6,056
58.4
%
Selling, general and administrative expenses (b)
1,798
16.3
%
1,721
16.6
%
Amortization of acquisition-related intangible assets
430
3.9
%
429
4.1
%
Research and development expenses
336
3.1
%
342
3.3
%
Restructuring and other costs (c)
49
0.4
%
98
1.0
%
Total costs and operating expenses
9,142
83.1
%
8,648
83.4
%
Operating income
1,863
16.9
%
1,716
16.6
%
Interest income
233
203
Interest expense
(354
)
(303
)
Other income/(expense) (d)
(9
)
3
Income before income taxes
1,734
1,620
Benefit from/(provision for) income taxes (e)
(70
)
(95
)
Equity in earnings/(losses) of unconsolidated entities
(8
)
(14
)
Net income
1,656
1,511
Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest
5
4
Net income attributable to Thermo Fisher Scientific Inc.
$
1,651
15.0
%
$
1,507
14.5
%
Earnings per share attributable to Thermo Fisher Scientific Inc.:
Basic
$
4.44
$
3.99
Diluted
$
4.43
$
3.98
Weighted average shares:
Basic
372
378
Diluted
373
379
Reconciliation of adjusted operating income and adjusted operating margin
GAAP operating income
$
1,863
16.9
%
$
1,716
16.6
%
Cost of revenues adjustments (a)
14
0.1
%
11
0.1
%
Selling, general and administrative expenses adjustments (b)
43
0.4
%
14
0.1
%
Restructuring and other costs (c)
49
0.4
%
98
1.0
%
Amortization of acquisition-related intangible assets
430
3.9
%
429
4.1
%
Adjusted operating income (non-GAAP measure)
$
2,399
21.8
%
$
2,269
21.9
%
Reconciliation of adjusted net income
GAAP net income attributable to Thermo Fisher Scientific Inc.
$
1,651
$
1,507
Cost of revenues adjustments (a)
14
11
Selling, general and administrative expenses adjustments (b)
43
14
Restructuring and other costs (c)
49
98
Amortization of acquisition-related intangible assets
430
429
Other income/expense adjustments (d)
1
(1
)
Income taxes adjustments (e)
(168
)
(122
)
Equity in earnings/losses of unconsolidated entities
8
14
Adjusted net income (non-GAAP measure)
$
2,027
$
1,950
Reconciliation of adjusted earnings per share
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc.
$
4.43
$
3.98
Cost of revenues adjustments (a)
0.04
0.03
Selling, general and administrative expenses adjustments (b)
0.12
0.04
Restructuring and other costs (c)
0.13
0.26
Amortization of acquisition-related intangible assets
1.15
1.13
Other income/expense adjustments (d)
0.00
0.00
Income taxes adjustments (e)
(0.45
)
(0.32
)
Equity in earnings/losses of unconsolidated entities
0.02
0.04
Adjusted EPS (non-GAAP measure)
$
5.44
$
5.15
Reconciliation of free cash flow
GAAP net cash provided by operating activities
$
1,192
$
723
Purchases of property, plant and equipment
(376
)
(362
)
Proceeds from sale of property, plant and equipment
9
12
Free cash flow (non-GAAP measure)
$
825
$
373
Business Segment Information
Three months ended
March 28,
% of
March 29,
% of
(Dollars in millions)
2026
Revenues
2025
Revenues
Revenues
Life Sciences Solutions
$
2,636
23.9
%
$
2,341
22.6
%
Analytical Instruments
1,716
15.6
%
1,718
16.6
%
Specialty Diagnostics
1,142
10.4
%
1,148
11.1
%
Laboratory Products and Biopharma Services
6,036
54.8
%
5,640
54.4
%
Eliminations
(524
)
-4.8
%
(482
)
-4.7
%
Consolidated revenues
$
11,005
100.0
%
$
10,364
100.0
%
Segment income and segment income margin
Life Sciences Solutions
$
954
36.2
%
$
834
35.6
%
Analytical Instruments
355
20.7
%
399
23.2
%
Specialty Diagnostics
313
27.4
%
304
26.5
%
Laboratory Products and Biopharma Services
778
12.9
%
731
13.0
%
Subtotal reportable segments
2,399
21.8
%
2,269
21.9
%
Cost of revenues adjustments (a)
(14
)
-0.1
%
(11
)
-0.1
%
Selling, general and administrative expenses adjustments (b)
(43
)
-0.4
%
(14
)
-0.1
%
Restructuring and other costs (c)
(49
)
-0.4
%
(98
)
-1.0
%
Amortization of acquisition-related intangible assets
(430
)
-3.9
%
(429
)
-4.1
%
Consolidated GAAP operating income
$
1,863
16.9
%
$
1,716
16.6
%
(a) Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and charges/(credits) for the sale of inventory revalued at the date of acquisition. Adjusted results in 2026 also exclude $3 of transaction-related costs.
(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs, and charges/credits for changes in estimates of contingent acquisition consideration. Adjusted results in 2026 also exclude $2 of accelerated depreciation on fixed assets to be abandoned due to facility consolidations.
(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and other matters, net gains/losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations.
(d) Adjusted results exclude net gains/losses on investments.
(e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements.
Note:
Consolidated depreciation expense is $306 and $276 in 2026 and 2025, respectively.
Organic revenue growth
Three months ended
March 28, 2026
Revenue growth
6%
Acquisitions
3%
Currency translation
2%
Organic revenue growth (non-GAAP measure)
1%
Note:
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.
Condensed Consolidated Balance Sheets (unaudited)
March 28,
December 31,
(In millions)
2026
2025
Assets
Current assets:
Cash and cash equivalents
$
3,254
$
9,852
Short-term investments
2
253
Accounts receivable, net
9,204
8,900
Inventories
5,496
5,425
Other current assets
4,361
4,278
Total current assets
22,316
28,707
Property, plant and equipment, net
10,658
10,565
Acquisition-related intangible assets, net
19,146
15,838
Other assets
5,973
5,871
Goodwill
55,187
49,362
Total assets
$
113,281
$
110,343
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations
$
3,090
$
3,533
Other current liabilities
11,531
11,656
Total current liabilities
14,621
15,189
Other long-term liabilities
6,527
5,766
Long-term obligations
40,071
35,852
Redeemable noncontrolling interest
121
122
Total equity
51,940
53,415
Total liabilities, redeemable noncontrolling interest and equity
$
113,281
$
110,343
Condensed Consolidated Statements of Cash Flows (unaudited)
Three months ended
March 28,
March 29,
(In millions)
2026
2025
Operating activities
Net income
$
1,656
$
1,511
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
736
706
Change in deferred income taxes
(258
)
(279
)
Other non-cash expenses, net
171
210
Changes in assets and liabilities, excluding the effects of acquisitions
(1,112
)
(1,425
)
Net cash provided by operating activities
1,192
723
Investing activities
Purchases of property, plant and equipment
(376
)
(362
)
Proceeds from sale of property, plant and equipment
9
12
Proceeds from cross-currency interest rate swap interest settlements
96
87
Acquisitions, net of cash acquired
(8,872
)
—
Purchases of investments
(14
)
(264
)
Proceeds from sales and maturities of investments
250
2
Other investing activities, net
(55
)
(1
)
Net cash used in investing activities
(8,961
)
(527
)
Financing activities
Net proceeds from issuance of debt
5,238
2,840
Repayment of debt
(1,412
)
(838
)
Proceeds from issuance of commercial paper
389
—
Purchases of company common stock
(3,000
)
(2,000
)
Dividends paid
(162
)
(149
)
Other financing activities, net
39
45
Net cash provided by (used in) financing activities
1,093
(102
)
Exchange rate effect on cash
78
37
Increase/(decrease) in cash, cash equivalents and restricted cash
(6,599
)
132
Cash, cash equivalents and restricted cash at beginning of period
9,879
4,040
Cash, cash equivalents and restricted cash at end of period
$
3,280
$
4,172
Free cash flow (non-GAAP measure)
$
825
$
373
Note:
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release.
Supplemental Information Regarding Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of acquisitions/divestitures and the effects of currency translation. We report these measures because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures, and/or foreign currency translation on revenues. Thermo Fisher management uses these measures to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.
We report adjusted operating income, adjusted operating margin, adjusted net income, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
Certain transaction-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction-related third-party costs, changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities are not indicative of our normal operating costs.
Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.
We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
Thermo Fisher Scientific does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions, transaction-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher Scientific’s results computed in accordance with GAAP.
The non-GAAP financial measures of Thermo Fisher Scientific’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher Scientific’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the tables above.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260422657369/en/
Media Contact Information:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Original: Thermo Fisher Scientific Reports First Quarter 2026 Results
US Market News
2月前
AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesApril 9, 2026 9:00 AM
InvestorsHub NewsWireAI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesAINewsWire Editorial Coverage: As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence directly into manufacturing workflows as a continuous compliance layer. Rather than depending on retrospective audits and manual checks, AI-driven technologies are now capable of monitoring, validating and optimizing production processes in real time to ensure alignment with evolving Good Manufacturing Practice ("GMP") requirements. This transformation is becoming increasingly visible across the sector and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), which operate at the intersection of biotechnology and advanced digital systems, reflecting a broader transition toward intelligent, automated compliance infrastructures. Through its focus on AI, Oncotelic sits alongside other innovation-driven organizations including Rockwell Automation Inc. (NYSE: ROK), Emerson Electric Co. (NYSE: EMR), Thermo Fisher Scientific Inc. (NYSE: TMO) and Danaher Corp. (NYSE: DHR), all of which are contributing to this evolving technological landscape.Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.Regulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing.Current obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.A more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Click here to view the custom infographic of the Oncotelic Therapeutics editorial.Embedded Intelligence Enables Continuous ComplianceHistorically, pharmaceutical manufacturing relied heavily on batch-based testing and manual recordkeeping to verify compliance. While these methods were sufficient in earlier production models, they often introduce delays and create opportunities for human error. Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.This shift supports initiatives from the U.S. Food and Drug Administration ("FDA"), which has encouraged the adoption of advanced manufacturing technologies and continuous production models. Programs such as the FDA's Emerging Technology Program and Advanced Manufacturing Technologies initiative promote the use of innovative systems designed to enhance reliability, improve product quality and minimize the risk of manufacturing failures or supply disruptions. These efforts highlight a transition from reactive oversight to proactive compliance strategies.AI technologies facilitate this transformation by regularly evaluating streams of production data, including variables such as temperature, pressure and material uniformity, to identify anomalies as they occur. Rather than detecting issues during post-production reviews, these systems enable immediate intervention, helping maintain product integrity. This ability supports real-time release testing, a model in which products are evaluated and approved based on live process data instead of delayed laboratory testing.As this approach gains adoption, companies such as Oncotelic Therapeutics are part of a broader ecosystem that increasingly views embedded intelligence as a core component of compliance. Their alignment with AI-enabled platforms reflects a growing understanding that compliance is no longer a discrete checkpoint, but an integrated function operating continuously across the manufacturing lifecycle.Heightened Regulation Accelerates Automation AdoptionRegulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The European Medicines Agency has released detailed guidance on computerized systems and data management, stressing the importance of secure, attributable and contemporaneous records. Likewise, FDA expectations reinforce following ALCOA+ principles, which ensure that data is attributable, legible, contemporaneous, original and accurate.These rising standards are hastening the move toward automation. Manual processes, which have long been standard across pharmaceutical manufacturing, are now seen as potential sources of variability and documentation risk. According to the International Society for Pharmaceutical Engineering, digital transformation initiatives are becoming essential to improving compliance outcomes and reducing operational risk in modern pharmaceutical systems.AI-enhanced automation provides a solution by standardizing workflows and ensuring consistent data capture. These systems automatically generate audit-ready documentation, reducing reliance on human input while improving transparency and accuracy. In sterile manufacturing environments, where contamination risks must be minimized, automation also reduces human involvement, thereby reinforcing compliance outcomes.Within this regulatory environment, Oncotelic Therapeutics represents a wider strategic alignment with innovation driven by compliance requirements. As pharmaceutical companies increasingly prioritize automation and data integrity, organizations leveraging AI-enabled platforms are better positioned to meet evolving regulatory expectations.Pharma 4.0 Drives Intelligent Production EcosystemsThe idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing. Sparked by Industry 4.0, this model integrates digital technologies such as artificial intelligence, robotics and advanced analytics into interconnected production systems. Research indicates that these technologies are transforming biopharma operations by increasing productivity, improving product quality and supporting more agile, data-driven decision-making across the value chain.In such environments, manufacturing systems are fully connected, enabling data to move between equipment, quality systems and supply chain processes. AI-driven analytics use this data to optimize performance, anticipate maintenance needs and ensure compliance. This integration enhances traceability, enabling manufacturers to monitor every stage of production with greater precision.Large pharmaceutical companies are now employing these capabilities. Pfizer Inc. has implemented digital manufacturing programs that leverage AI and data-driven systems to improve efficiency and operational performance. Johnson & Johnson has invested in AI-powered platforms to enhance decision-making and streamline development processes, while Novartis AG is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments. These initiatives demonstrate a broader industry commitment to adopting intelligent manufacturing as a pathway to improved compliance and operational efficiency.Within this context, Oncotelic Therapeutics represents a growing class of entities operating at the intersection of biotechnology and digital innovation. As Pharma 4.0 adoption increases, organizations supporting AI-enabled systems are increasingly positioned to participate in scalable, data-driven manufacturing ecosystems.Efficiency Gains Reduce Cost, RiskThe process of bringing a new pharmaceutical product to market remains both time-consuming and expensive, often requiring more than a decade of development and substantial financial investment. A substantial part of these expenses are caused by high failure rates, increasing process complexity and inefficiencies across development and manufacturing stages. These obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.Deloitte has noted that digital transformation in life sciences manufacturing can boost operational efficiency by streamlining processes, increasing productivity and reducing errors. AI systems can evaluate both real-time and historical data to anticipate possible problems, allowing manufacturers to intervene before issues escalate.Continuous manufacturing, frequently supported by AI and advanced process control technologies, further improves efficiency by reducing reliance on large-batch production. Instead, it enables continuous processing with real-time monitoring, lowering inventory requirements and accelerating time-to-market. The FDA has actively supported this approach, recognizing its ability to improve product quality, reduce costs and provide a more flexible alternative to traditional batch manufacturing.The combination of reduced risk and improved efficiency creates a compelling value proposition for companies operating at the intersection of AI and biotechnology. In this environment, organizations such as Oncotelic Therapeutics reflect the growing importance of platforms capable of supporting intelligent automation and compliance as the industry seeks to manage costs more effectively.AI, Robotics Reshape Biotech InfrastructureA more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Modern manufacturing facilities increasingly rely on robotic systems to automate complex processes such as aseptic filling, material handling and inspection, decreasing the need for human intervention while improving precision and efficiency. In addition, AI-driven systems monitor operations in real time, analyzing data to detect irregularities and optimize performance, supporting continuous compliance.This meeting of technology is especially significant in sterile manufacturing environments, where minimizing human involvement is essential to reducing contamination risk. Robotics provide precision and consistency, while AI systems continuously monitor environmental conditions and process variables. These technologies come together to make integrated systems that sustain both compliance and operational quality.Market data highlights the reach of this transformation. The global pharmaceutical manufacturing sector, already valued in the hundreds of billions of dollars, is expected to reach $1 trillion in the coming years. Investment is increasingly directed toward automation, digital infrastructure and AI-enabled production systems designed to improve efficiency and regulatory compliance. This trend indicates a broader reallocation of capital toward technologies that enhance scalability, precision and operational control.As this movement continues to climb upward, companies aligned with AI-driven platforms may benefit from sustained growth and improved margins. Positioned within this evolving landscape, Oncotelic Therapeutics represents the type of organization that could participate in this transformation, where intelligent automation and integrated compliance redefine pharmaceutical manufacturing.AI and Robotics Drive Next Phase of TransformationArtificial intelligence and robotics are rapidly reshaping industrial operations, enabling companies to improve efficiency, reduce manual intervention and unlock new levels of productivity. Across manufacturing, infrastructure and life sciences, organizations are increasingly deploying intelligent automation systems that combine real-time data, machine learning and advanced robotics to streamline workflows and support decision-making.Rockwell Automation Inc. (NYSE: ROK) announced a major step in real-time intelligence for industrial teams. The company introduced its integration of NVIDIA Nemotron Nano, a purpose-built small language model ("SLM") optimized for FactoryTalk(R) Design Studio(TM) and other Rockwell product workflows. In collaboration with NVIDIA, Rockwell is leveraging the open-source Nemotron-Nano-9B-v2 model and NVIDIA NeMo to deliver an edge-based generative AI capability designed specifically for industrial environments.Emerson Electric Co. (NYSE: EMR) has introduced a new AI-powered environment to enhance upstream lifecycle decision making. Emerson's AspenTech Subsurface Intelligence(TM) ("ASI") is an open, cloud-native agentic environment that incorporates AI to transform the user experience and accelerate subsurface-related decision making while leveraging existing investments in legacy applications. ASI fulfills a critical industry need to work in an agile, multidisciplinary manner, optimize production and improve access to information trapped throughout various parts of the organization.Thermo Fisher Scientific Inc. (NYSE: TMO) integrates AI and robotics into laboratory and semiconductor environments with its Thermo Scientific Vulcan(TM) Automated Lab. The platform is designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system enhances productivity, increases yield and reduces operating costs for semiconductor manufacturers.Danaher Corp. (NYSE: DHR) announced a collaboration designed to enhance life science lab connectivity by integrating automated imaging and detection systems into research workflows. Molecular Devices, LLC., a leading provider of high-performance life science solutions and an operating company of Danaher is partnering with Automata, a London-based lab automation company developing fully integrated, AI-ready platforms for life science researchers. As labs face mounting pressure to boost throughput and data quality while managing limited hands-on resources, new integrations between Molecular Devices' imaging and detection systems and Automata's LINQ platform will provide a scalable, interoperable foundation for fully connected research workflows.These developments reflect a broader transformation across industrial and scientific sectors, where AI and robotics are becoming foundational technologies rather than experimental tools. As companies continue to integrate intelligent systems into core operations, these advancements highlight the growing importance of automation in driving efficiency, scalability and long-term competitiveness across the global economy.For more information, visit Oncotelic Therapeutics Inc.
Original: AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
US Market News
4月前
Thermo Fisher Scientific Prices Offering of USD-Denominated Senior NotesFebruary 9, 2026 9:41 PM
Business Wire
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $3.8 billion aggregate principal amount (the “Offering”) of the following notes:
$1.0 billion aggregate principal amount of its 4.215% senior notes due 2031 (the “2031 notes”) at the issue price of 100.000% of their principal amount;
$750 million aggregate principal amount of its 4.550% senior notes due 2033 (the “2033 notes”) at the issue price of 99.783% of their principal amount;
$1.3 billion aggregate principal amount of its 4.902% senior notes due 2036 (the “2036 notes”) at the issue price of 100.000% of their principal amount; and
$750 million aggregate principal amount of its 5.546% senior notes due 2046 (the “2046 notes” and, together with the 2031 notes, the 2033 notes and the 2036 notes, the “notes”) at the issue price of 100.000% of their principal amount.
The Offering is expected to close on or about February 12, 2026, subject to the satisfaction of customary closing conditions. The notes will pay interest on a semi-annual basis.
Thermo Fisher intends to use the net proceeds from the sale of the notes to pay a portion of the cash consideration payable for the pending acquisition of Clario Holdings, Inc. (the “Clario Acquisition”). Pending completion of the Clario Acquisition, Thermo Fisher may also determine to use a portion of the net proceeds of the Offering for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures or the repurchase of its outstanding equity securities or it may temporarily invest the net proceeds in short-term, liquid investments until they are used for their ultimate purpose.
The joint book-running managers for the Offering are Deutsche Bank Securities Inc., RBC Capital Markets, LLC, SMBC Nikko Securities America, Inc. and Wells Fargo Securities, LLC.
The Offering is being made pursuant to an effective registration statement on Form S-3ASR (File No. 333-285159) filed by Thermo Fisher with the U.S. Securities and Exchange Commission (the “SEC”) on February 24, 2025 and only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and an issuer free writing prospectus have been filed, and a prospectus supplement relating to the Offering will be filed, with the SEC, to which this communication relates. Prospective investors should read the issuer free writing prospectus, preliminary prospectus supplement and accompanying prospectus forming a part of that registration statement and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and the Offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any dealer participating in the Offering will arrange to send you the prospectus and the prospectus supplement if you request it by calling Deutsche Bank Securities Inc. toll-free at 1-800-503-4611, RBC Capital Markets, LLC toll-free at 1-866-375-6829, SMBC Nikko Securities America, Inc. toll-free at 1-888-868-6856, or Wells Fargo Securities, LLC toll-free at 1-800-645-3751.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about timing and completion of the Offering, Thermo Fisher’s intended use of proceeds therefrom, and the pending Clario Acquisition. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the Offering and the Clario Acquisition. Additional important factors and information regarding Thermo Fisher’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” section of the prospectus dated February 24, 2025 and the preliminary prospectus supplement dated February 9, 2026 related to the Offering and in Part 1, Item 1A. “Risk Factors” of Thermo Fisher’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the other documents incorporated by reference into the prospectus and prospectus supplement, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260209260733/en/
Media Contact Information:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Original: Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
Pro-Life
15年前
Thermo Fisher Scientific to Acquire Dionex Corporation
Date : 12/13/2010 @ 7:00AM
Source : Business Wire
Stock : Thermo Fisher Scientific (TMO)
http://ih.advfn.com/p.php?pid=nmona&article=45623768&symbol=TMO
Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, and Dionex Corporation (NASDAQ: DNEX), a leading manufacturer and marketer of chromatography systems, today announced that their Boards of Directors have unanimously approved a transaction under which Thermo Fisher will acquire all of the outstanding shares of Dionex for $118.50 per share in cash, or a total purchase price of approximately $2.1 billion. The transaction is not conditioned on financing and is expected to be completed in the first quarter of 2011.
Under the terms of the agreement, Thermo Fisher will commence a tender offer to acquire all of the outstanding shares of Dionex common stock for $118.50 per share in cash. The consideration represents a 21% premium to Dionex’s closing stock price on December 10, 2010, the last trading day prior to today’s announcement and a 32% premium to Dionex’s average closing stock price over the last 60 trading days. Thermo Fisher expects to realize total operating synergies of $60 million in year three following the transaction’s close through a combination of cost savings and revenue enhancements. The transaction is expected to be immediately accretive to Thermo Fisher’s adjusted earnings per share by $0.13 to $0.15 in the first 12 months following the close. Adjusted earnings per share and adjusted operating income are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”
Dionex, based in Sunnyvale, Calif., introduced the first ion chromatography system for water analysis shortly after its founding in 1975 and has consistently grown through innovation and global expansion. Today, the company has more than 1,600 employees in 21 countries spanning six continents, including a significant presence in the Asia-Pacific region. Dionex will be integrated into Thermo Fisher’s Analytical Technologies Segment.
“We believe the combination of Thermo Fisher and Dionex is extremely compelling from a technology, market and financial perspective,” said Marc N. Casper, president and chief executive officer of Thermo Fisher. “Dionex’s strength in chromatography instruments, software and consumables complements our leading positions in mass spectrometry and laboratory information management systems. The transaction, which we expect to be immediately accretive, is consistent with our strategy of accelerating growth by increasing our depth of capabilities to serve attractive end markets. Specifically, it complements our strong presence in China, where we’ve established the headquarters for our global environmental instruments business and continue to build our commercial infrastructure to meet the needs of customers in growing water quality, consumer safety and life sciences markets.”
“We are pleased to be joining Thermo Fisher and are excited about the opportunities we will have as part of the world leader in serving science,” said Frank Witney, president and chief executive officer of Dionex. “Thermo Fisher’s commitment to innovation will fuel our ongoing technology development, and their global manufacturing and commercial presence will significantly strengthen our ability to deliver quality products and services to our customers around the world. This transaction offers immediate and significant value for our shareholders, as well as the opportunity for our customers and employees to benefit from combining two highly complementary organizations. We look forward to working closely with the Thermo Fisher team to ensure a smooth transition and complete the transaction as expeditiously as possible.”
Mr. Casper continued, “We are delighted to welcome Dionex’s talented and dedicated employees to our team. Together, we will offer our customers new solutions based on a powerful combination of leading instruments, software, consumables and services.”
Benefits of the Transaction
- Creates a Leading Chromatography Offering: The transaction brings two complementary chromatography portfolios together to create the most extensive chromatography instruments, software and consumables offering in the industry. Specifically, it combines Dionex’s ion and liquid chromatography systems and consumables with Thermo Fisher’s gas chromatography systems and consumables.
- Improves Performance and Productivity: Customers will benefit from the combination of Thermo Fisher’s leadership in mass spectrometry with Dionex’s comprehensive chromatography offering. By integrating these leading technologies and related software, Thermo Fisher will be able to deliver exceptional performance and productivity for customers through improved sample analysis and data management.
- Strengthens Software Growth Platform: Dionex’s gold standard chromatography data system coupled with Thermo Fisher’s leading enterprise laboratory information management systems creates the most comprehensive desktop and enterprise software capabilities in the industry. This combination will significantly improve performance, productivity and compliance for customers to maximize their return on investment.
- Expands Presence in Applied Markets: Thermo Fisher will benefit from Dionex’s significant customer base and relationships in attractive applied markets, including environmental analysis, food safety and other industrial sectors. Through this combination, Thermo Fisher will be able to deliver unmatched analytical solutions for a growing range of testing needs, particularly water analysis, where growth is driven by new regulatory requirements and increased testing in developing countries such as China.
- Increases Footprint in Asia-Pacific: Dionex currently generates more than 35% of its revenues in Asia-Pacific and other emerging high-growth geographies. The company has a history of growth in the region by establishing a strong reputation through its well-regarded direct sales and service presence there. This transaction is consistent with Thermo Fisher’s strategy of investing to increase its footprint in Asian markets, such as China and India, as well as other strategic growth markets, like Brazil.
- Offers Significant Synergies: The transaction is expected to generate a total of approximately $60 million of cost and revenue synergies in year three after the transaction’s close. This includes approximately $40 million from cost-related synergies and $20 million of adjusted operating income benefit from revenue-related synergies.
Mr. Casper concluded, “The acquisition of Dionex is another example of the great progress we’re making in executing on our strategy to accelerate growth. We have invested in technology innovation, Asia expansion and complementary acquisitions – all to strengthen our growth opportunities in attractive end markets. We are focused on these strategic investments because they create value for all our key stakeholders – customers, employees and shareholders.”
Financing and Approvals
Thermo Fisher intends to use cash on hand and proceeds from committed financing from Barclays Capital and J.P. Morgan Securities LLC to facilitate the transaction. The transaction, which is expected to be completed in the first quarter of 2011, is subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.
Advisors
Barclays Capital and J.P. Morgan Securities LLC are acting as financial advisors to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel. Goldman, Sachs & Co. is acting as financial advisor to Dionex, and Cooley LLP is serving as legal counsel.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measures adjusted operating income and adjusted earnings per share. Adjusted operating income excludes restructuring and other costs/income and amortization of acquisition-related intangible assets. Adjusted earnings per share also excludes certain other gains and losses, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and discontinued operations. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts.
Conference Call and Webcast
Thermo Fisher and Dionex will host a conference call and Webcast at 8:30 a.m. EST today to provide more information on this announcement. The Webcast and accompanying slides can be accessed at www.thermofisher.com and www.dionex.com. An audio archive of the call will be available on both companies’ Websites until December 27, 2010, at 11:59 pm EST.
Conference Call Dial-in: Domestic: (866) 610-1072
International: (973) 935-2840
Passcode: 31400437
Replay Dial-in: Domestic: (800) 642-1687
International: (706) 645-9291
Passcode: 31400437
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
iHub News
2月前
Ned857
2年前
Monksdream
2年前
BOS
5年前
BoilerRoom
6年前
Investorr
7年前
ValueInvestor15
9年前
Penny Roger$
14年前
メールアドレスで登録
